AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Fidelis Capital Partners LLC

Fidelis Capital Partners LLC boosted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 9.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 17,491 shares of the company’s stock after acquiring an additional 1,478 shares during the period. Fidelis Capital Partners LLC’s holdings in AstraZeneca were worth $1,346,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Farmers & Merchants Investments Inc. purchased a new position in shares of AstraZeneca in the 3rd quarter valued at about $78,000. Diversify Advisory Services LLC grew its holdings in AstraZeneca by 1.4% in the third quarter. Diversify Advisory Services LLC now owns 15,769 shares of the company’s stock valued at $1,219,000 after purchasing an additional 221 shares during the period. Integrated Advisors Network LLC increased its position in shares of AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after buying an additional 13,860 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of AstraZeneca by 101.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 119,382 shares of the company’s stock worth $9,301,000 after buying an additional 59,999 shares during the period. Finally, Autumn Glory Partners LLC purchased a new position in shares of AstraZeneca during the 3rd quarter valued at approximately $594,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Finally, TD Cowen boosted their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Stock Down 1.0 %

AZN stock opened at $75.22 on Wednesday. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The firm has a 50-day moving average of $80.03 and a two-hundred day moving average of $78.68. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $87.68. The company has a market cap of $233.23 billion, a price-to-earnings ratio of 36.34, a PEG ratio of 1.39 and a beta of 0.46.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.